secwatch.observer — SEC 8-K summary
======================================

Issuer:     Turn Therapeutics Inc. (TTRX)
CIK:        0002023016
Form:       8-K
Filed at:   2026-09-10T12:10:38+00:00
Accession:  0001213900-26-098584
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Turn Therapeutics to present at Stifel 2026 Virtual Immunology and Inflammation Forum
--------------------------------------------------------------------------------

- CEO Bradley Burnam and Dr. Stephen M. Hahn to present on September 23, 2026 at 1:30 PM ET.
- Presentation covers atopic dermatitis program, including pruritus-focused stage 2 enrichment strategy.
- Emerging findings across patient populations: moderate-severe baseline pruritus and lower EASI with high IGA.
- Live webcast on company website; replay available for approximately six months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2023016/000121390026098584/0001213900-26-098584-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2023016/000121390026098584/ea0305037-8k_turn.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-098584

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer